SMARCA4 and sarcoma: A total of 98 patients were enrolled in the sarcoma cohort [88], including 34 with chordoma, 14 with ASPS, 11 with SMARCA4-deficient malignant rhabdoid tumor (SMRT), 8 with desmoplastic small round cell tumor (DSRCT) and 31 with other histotypes.